SPONSORED: UBS Asset Management – Supply/demand imbalance in the UK life sciences sector presents opportunity for experienced investor

Accelerated by the pandemic, the demand for UK life sciences space is skyrocketing amid a paucity of appropriate supply. “Vacancy rates have ultimately fallen to zero and have stayed at 0 percent for a few years,” notes Zachary Gauge, head of Real Estate Research & Strategy, Europe, for UBS Asset Management, in an interview published in the July/August issue of Institutional Real Estate Europe. “Venture capital funding is increasingly going to companies in the United Kingdom, particularly in Oxford, Cambridge and London. Combined, this is a large market, but in terms of life sciences space and availability, it offers very limited existing stock, and much of the stock that does exist is outdated.” Gauge goes on to discuss the medical research opportunities he is most excited about, along with the challenges investors are likely to face navigating the UK market. To access a pdf of the Sponsored Section,